Dr. Michael Tymianski founded NoNO Inc. in 2003 to commercialize development technology stemming from his research laboratory. Dr. Tymianski has been the President and CEO of the Company since its inception, and has propelled its lead technologies from the discovery stage to ongoing late-stage pivotal clinical trials. While executing on the vision and strategic directions of the Company, Dr. Tymianski has assembled on of Canada’s most dynamic biotechnology discovery teams, ranging from drug and target validation, chemistry, preclinical IND-endabling research, and through to clinical operations culminating in to global clinical trials. He was also the Head of the Division of Neurosurgery at the University Health Network in Toronto or 8 years and is a Professor of Surgery and Physiology at the University of Toronto, providing the company with unique insights into academic preclinical and clinical and research teams. He is the Harold and Esther Halpern Chair in Neurosurgical Stroke Research and a Canada Research Chair (Tier 1) in Translational Stroke Research. Dr. Tymianski was appointed as a member of the Order of Canada in December 2016.